 |
16 Diseases |  |
1 Trial |
|
1 Trial |  |
7 News |  |
- | ispronicline (AZD3480) / AstraZeneca
Journal: Nicotine-like discriminative and aversive effects of two α4β2-selective nicotine agonists, ispronicline and metanicotine. (Pubmed Central) - Feb 15, 2022
Both ispronicline and metanicotine as well as nicotine were avoided in the drug + food vs. food choice situation. The receptor-selective nature of ispronicline and metanicotine was hereby confirmed in a behavioral assay, as were earlier reports that the discriminative stimulus effects of relatively small doses of nicotine are likely mediated by activity at the α4β2* nicotine receptor.
- | arecoline / Cogent
Journal: Nicotinic aspects of the discriminative stimulus effects of arecoline. (Pubmed Central) - Feb 15, 2022
These data indicate a selective α4β2* nicotine receptor component to the behavioral effects of arecoline. Although the nicotinic aspects of arecoline's behavior effects could suggest that abuse of arecoline-containing material (e.g. betel nut chewing) is mediated through nicotinic rather than muscarinic actions, further research, specifically on the reinforcing effects of arecoline, is necessary before this conclusion can be supported.
- ispronicline (AZD3480) / AstraZeneca
Enrollment change, Trial termination: Pharmacokinetic Interaction Between AZD3480 and Donepezil (clinicaltrials.gov) - Jul 30, 2014
P1, N=33, Terminated, Sponsor: AstraZeneca
Although the nicotinic aspects of arecoline's behavior effects could suggest that abuse of arecoline-containing material (e.g. betel nut chewing) is mediated through nicotinic rather than muscarinic actions, further research, specifically on the reinforcing effects of arecoline, is necessary before this conclusion can be supported. N=20 --> 33 | Suspended --> Terminated; Ended prematurely - The trial never commenced.
- |||| ispronicline (AZD3480) / AstraZeneca
Trial completion, Enrollment change, Monotherapy: Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD) (clinicaltrials.gov) - Jul 16, 2014
P2, N=386, Completed, Sponsor: Targacept Inc.
N=20 --> 33 | Suspended --> Terminated; Ended prematurely - The trial never commenced. Active, not recruiting --> Completed | N=300 --> 386
- |||| ispronicline (AZD3480) / AstraZeneca
Trial completion: A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI) (clinicaltrials.gov) - Feb 22, 2014
P2, N=174, Completed, Sponsor: Targacept Inc.
Active, not recruiting --> Completed | N=300 --> 386 No longer recruiting --> Completed
- ||| ispronicline (AZD3480) / AstraZeneca
Enrollment closed, Monotherapy: Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD) (clinicaltrials.gov) - May 7, 2013
P2, N=300, Active, not recruiting, Sponsor: Targacept Inc.
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| ispronicline (AZD3480) / AstraZeneca
New P2 trial, Monotherapy: Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD) (clinicaltrials.gov) - Nov 3, 2011
P2, N=300, Active, not recruiting, Sponsor: Targacept Inc.